HIV and COVID-19: juxtaposition of two pandemics

Affiliations

Comment

John Nkengasong. Lancet HIV. 2022 May.

. 2022 May;9(5):e300-e301.

doi: 10.1016/S2352-3018(22)00095-9.

¹ Africa Centres for Disease Control and Prevention, Addis Ababa W21K19, Ethiopia. Electronic address: nkengasongj@africa-union.org.

No abstract available

Conflict of interest statement

I declare no competing interests.

Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study.
Netto LC, Ibrahim KY, Picone CM, Alves APPS, Aniceto EV, Santiago MR, Parmejani PSS, Aikawa NE, Medeiros-Ribeiro AC, Pasoto SG, Yuki EFN, Saad CGS, Pedrosa T, Lara AN, Ceneviva C, Bonfa E, Kallas EG, Avelino-Silva VI. Netto LC, et al. Lancet HIV. 2022 May;9(5):e323-e331. doi: 10.1016/S2352-3018(22)00033-9. Epub 2022 Mar 23. Lancet HIV. 2022. PMID: 35338835 Free PMC article.
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial.
Madhi SA, Moodley D, Hanley S, Archary M, Hoosain Z, Lalloo U, Louw C, Fairlie L, Fouche LF, Masilela MSL, Singh N, Grobbelaar C, Ahmed K, Benadé G, Bhikha S, Bhorat AE, Bhorat Q, Joseph N, Dheda K, Esmail A, Foulkes S, Goga A, Oommen Jose A, Kruger G, Kalonji DJ, Lalloo N, Lombaard JJ, Lombard Koen A, Kany Luabeya A, Mngqibisa R, Petrick FG, Pitsi A, Tameris M, Thombrayil A, Vollgraaff PL, Cloney-Clark S, Zhu M, Bennett C, Albert G, Faust E, Plested JS, Fries L, Robertson A, Neal S, Cho I, Glenn GM, Shinde V; 2019nCoV-501 Study Group. Madhi SA, et al. Lancet HIV. 2022 May;9(5):e309-e322. doi: 10.1016/S2352-3018(22)00041-8. Lancet HIV. 2022. PMID: 35489376 Free PMC article. Clinical Trial.

1. WHO HIV/AIDS: key facts. Nov 30, 2021. https://www.who.int/news-room/fact-sheets/detail/hiv-aids
1. Netto LC, Ibrahim KY, Picone CM, et al. Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study. Lancet HIV. 2022 doi: 10.1016/S2352-3018(22)00033-9. published online March 23. - DOI - PMC - PubMed
1. Madhi SA, Koen AL, Izu A, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV. 2021;8:e568–e580. - PMC - PubMed
1. Madhi SA, Moodley D, Hanley S, et al. Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised controlled phase 2A/2B trial. Lancet HIV. 2022;5:e309–e322. - PMC - PubMed
1. Cele S, Karim F, Lustig G, et al. SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. Cell Host Microbe. 2022;30:154–162. - PMC - PubMed